Myositis Interstitial Lung Disease Nintedanib Trial

NCT05799755 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

49

Enrollment

OTHER

Sponsor class

Conditions

Myositis Associated Interstitial Lund Disease (MA-ILD)

Interventions

DRUG: Nintedanib
DRUG: Placebo
DRUG: Standard of Care

Sponsor

Rohit Aggarwal, MD

Collaborators

[object Object]